Replies to post #162138 on Biotech Values

[DewDiligence]

Ipsen—the maker of Dysport—announced two botulinum-toxin deals today: a research collaboration with Harvard University and the acquisition of private biotech firm, Syntaxin:

http://finance.yahoo.com/news/ipsen-announce-sponsored-research-agreement-050000844.html (Harvard)

http://finance.yahoo.com/news/ipsen-strengthens-neurology-r-d-050000369.html (Syntaxin)

The Syntaxin acquisition is for $37M with a $170M earn-out.